Drug intelligence / Profile preview

pembrolizumab + MK-3120

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Pembrolizumab + MK-3120 is an investigational combination therapy comprising pembrolizumab, a PD-1 immune checkpoint inhibitor monoclonal antibody, and MK-3120, an investigational agent in clinical development by Merck. Pembrolizumab blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), thereby enhancing T-cell mediated immune response against tumor cells. MK-3120’s precise target mechanism is not specified in publicly available sources as of September 2025, but it is under investigation for safety and efficacy in advanced solid tumors. The combination is being studied for the treatment of various advanced solid malignancies, aiming to improve immune-mediated antitumor activity.

Other names: MK-3475MK3475MK 3475pembrolizumab (MK-3475)KeytrudaMK-3120MK3120MK 3120

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on pembrolizumab + MK-3120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + MK-3120.

Explore the full profile